• Inhibitor Therapeutics held its annual stockholders meeting on Sept. 15, 2026.
• Stockholders selected six directors for one-year terms expiring at the 2027 annual meeting.
• Cherry Bekaert was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Stockholders adopted the 2025 Share Incentive Plan.
• A non-binding advisory vote endorsed executive compensation.
• Stockholders favored holding future non-binding advisory votes on executive compensation every three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-043331), on September 18, 2026, and is solely responsible for the information contained therein.